medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Number 4

<< Back Next >>

Ann Hepatol 2005; 4 (4)

Hereditary Hemochromatosis: Genetics, Pathogenesis, and Clinical Management

Alexander J, Kowdley KV

Language: Spanish
References: 40
Page: 240-247
PDF size: 89.39 Kb.


Text Extraction

Recent findings have led to major advances in our understanding of genetics and pathophysiology of hereditary hemochromatosis. Many crucial genes and molecules have come to light, and the complex interrelationships between them are being studied. However, several questions still remain unanswered. Availability of genotyping has changed the approach to diagnosis, and serum markers hold promise for prognostication. However, the effectiveness of population screening continues to be an area of controversy. Finally, there is a promise of development of newer therapeutic modalities based on our understanding of the mechanism of iron absorption. In this review, we describe the current state of understanding in the clinical features, pathophysiology and treatment of hereditary hemochromatosis.


REFERENCES

  1. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13(4): 399-408.

  2. Hemochromatosis. In: Online Mendelian Inheritance in Man, OMIM, Ed. McKusick VA, Accessed Nov. 10, 2005 at http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=235200

  3. Wallace DF, Walker AP, Pietrangelo A, Clare M, Bomford AB, Dixon JL, et al. Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. J Hepatol 2002; 36(4): 474-9.

  4. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34(4): 275-8.

  5. Rochette J, Pointon JJ, Fisher CA, Perera G, Arambepola M, Arichchi DS, et al. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet 1999; 64: 1056-62.

  6. Cazzola M, Cerani P, Rovati A, Iannone A, Claudiani G, Bergamaschi G. Juvenile genetic hemochromatosis is clinically and genetically distinct from the classical HLA related disorder. Blood 1998; 92: 2979-81.

  7. Nelson JE, Kowdley KV. Non-HFE Hemochromatosis: Genetics, Pathogenesis, and Clinical Management. Curr Gastroenterol Rep 2005; 7(1): 71-80.

  8. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004; 350(23): 2383-97.

  9. De Domenico I, Ward DM, Nemeth E, Vaughn MB, Musci G, Ganz T, Kaplan J. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci USA 2005; 102(25): 8955-60.

  10. Beutler E, Barton JC, Felitti VJ, Gelbart T, West C, Lee PL, Waalen J, et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003; 31(3): 305-9.

  11. Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998; 95: 1472-7.

  12. Whittington CA, Kowdley KV. Review article: haemochromatosis. Aliment Pharmacol Ther 2002; 16(12): 1963-75.

  13. Smith PM, Godfrey BE, Williams R. Iron absorption in idiopathic haemochromatosis and its measurement using a whole-body counter. Clin Sci 1969; 37: 519-31.

  14. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306(5704): 2090-3.

  15. Beaumont C, Canonne-Hergaux F. Erythrophagocytosis and recycling of heme iron in normal and pathological conditions; regulation by hepcidin. Transfus Clin Biol 2005; 12(2): 123-30.

  16. Ganz T. Hepcidin- a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005; 18(2): 171-82.

  17. Frazer DM, Wilkins SJ, Becker EM, Vulpe CD, McKie AT, Trinder D, Anderson GJ. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology 2002; 123(3): 835-44.

  18. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004; 117(3): 285-97.

  19. Andrews NC. Molecular control of iron metabolism. Best Pract Res Clin Haematol 2005; 18(2): 159-69.

  20. Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol 2005; 100(4): 837-41.

  21. O’neil J, Powell L. Clinical aspects of hemochromatosis. Semin Liver Dis 2005; 25(4): 381-91.

  22. De Gobbi M, Roetto A, Piperno A, Mariani R, Alberti F, Papanikolaou G, et al. Natural history of juvenile haemochromatosis. Br J Haematol 2002; 117(4): 973-9.

  23. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 1321-8.

  24. Bassett ML, Halliday JW, Ferris RA, Powell LW. Diagnosis of hemochromatosis in young subjects: Predictive accuracy of biochemical screening tests. Gastroenterology 1984; 87: 628-633.

  25. Adams PC, Reboussin DM, Leiendecker-Foster C, Moses GC, McLaren GD, McLaren CE, Dawkins FW, et al. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the hemochromatosis and iron overload screening (HEIRS) study. Clin Chem 2005; 51(6): 1048-52.

  26. Keeffe EB. Liver transplantation in patients with hepatic iron overload: favorable or unfavorable outcome? Hepatology 2000; 32(6): 1396-8.

  27. Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, Gordon SC, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138(8): 627-33. Erratum in: Ann Intern Med 2003; 139(3): 235.

  28. Bissell DM. Assessing fibrosis without a liver biopsy: are we there yet? Gastroenterology 2004; 127(6): 1847-9.

  29. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127(6): 1704-13.

  30. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105(2): 855-61.

  31. Stickel F, Osterreicher CH, Datz C, Ferenci P, Wolfel M, Norgauer W, Kraus MR, et al. Prediction of progression to cirrhosis by a glutathione S- transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med 2005; 165(16): 1835-40.

  32. Osterreicher CH, Datz C, Stickel F, Hellerbrand C, Penz M, Hofer H, Wrba F, et al. Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. J Hepatol 2005; 42(6): 914-9.

  33. Osterreicher CH, Datz C, Stickel F, Hellerbrand C, Penz M, Hofer H, Wrba F, et al. TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine 2005; 31(2): 142-8.

  34. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313(20): 1256-62.

  35. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991; 101(2): 368-72.

  36. Wojcik JP, Speechley MR, Kertesz AE, Chakrabarti S, Adams PC. Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol 2002; 16(5): 297-302.

  37. Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, Fontana RJ, et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005; 129(2): 494-503.

  38. Brandhagen DJ, Alvarez W, Therneau TM, Kruckeberg KE, Thibodeau SN, Ludwig J, Porayko MK. Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. Hepatology 2000; 31(2): 456-60.

  39. Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 2005; 18(2): 289-98.

  40. Ezquer F, Nunez MT, Israel Y. Antisense gene delivered by an adenoassociated viral vector inhibits iron uptake in human intestinal cells: potential application in hemochromatosis. Biochem Pharmacol 2005; 69(11): 1559-66.




2020     |     www.medigraphic.com